Introduction

Adherence to multiple inhaler triple therapy (MITT) in COPD patients is known to be poor. Single inhaler triple therapy (SITT) may improve adherence by reducing regimen complexity for patients. We investigated real-world comparative adherence of SITT vs MITT in patients with COPD in Japan.

Methods

This retrospective analysis of Japanese Medical Data Vision data indexed patients on the first prescription of SITT (fluticasone furoate/umeclidinium/vilanterol or budesonide/glycopyrronium/formoterol) or MITT between Sept-19?Jul-21.

Eligible patients had ?1 inpatient or ?2 outpatient COPD diagnostic codes aged ?40 years prior to index, and continuous registration for 12 months pre- and 6 months post-index. Inverse probability of treatment weighting was used to balance baseline characteristics.

Adherence to SITT or MITT was measured using the proportion of days covered (PDC). Mean PDC and proportions of adherent patients (PDC?80%) were evaluated.

Results

We included 5537 patients (SITT: 2962; MITT: 2575). Mean age was 71.8 (SD 11.6) for MITT users and 74.3 (9.3) for SITT users. Patients were mostly male (MITT: 66.4%; SITT: 77.9%). PDC endpoints are presented in Table 1.

Conclusions

Patients with COPD in Japan newly initiating SITT have statistically significantly better adherence compared with patients initiating MITT.

Funding: GSK (217615)